Bofa Upgrades Moderna After 177% Rally - Aug 20

The Story

Bank of America upgraded Moderna to Neutral with a $170 price objective after the stock jumped following positive data on its personalized cancer vaccine, intismeran. $MRNA is reported at $122.51, with several data points now in focus after the roughly 177% rally.

Why It Matters For Your Portfolio

• $MRNA has surged, with the headline rally at about 177% and reported datapoints including 100.58% and 41.62%, signaling large recent gains that can reshape portfolio exposure to biotech risk and reward.
• BofA's Neutral call and $170 price objective frame potential upside versus current reported levels, and they give investors a new valuation reference point for risk sizing.
• Reported figures such as 0.24% and 100% alongside the $122.51 price suggest volatility remains high, which can amplify both short-term trading moves and longer-term valuation swings.
• Upcoming catalysts tied to intismeran clinical readouts and regulatory steps could move the stock materially, making monitoring of news flow important for position management.

The Trade

Growth and biotech-focused investors should note the fresh analyst lens and the $170 price objective as a valuation anchor, while traders can expect continued volatility around clinical and regulatory updates. Do you have exposure to $MRNA? Watch upcoming trial readouts, regulatory notices, and price action versus the $170 target as the next catalysts to gauge momentum and risk.